Important: No clinical trials exist for KLOW specifically. Kisspeptin research is in reproductive physiology and fertility — not metabolic weight loss. Consumer framing of kisspeptin analogs for weight management or metabolic health extrapolates beyond the evidence base.
Overview
Kisspeptin-10 (KLOW) is the biologically active C-terminal decapeptide fragment of kisspeptin, a neuropeptide encoded by the KISS1 gene that serves as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Discovered in 2001 as the endogenous ligand for the orphan receptor GPR54 (now designated KISS1R), kisspeptin has since been recognized as the critical upstream signal that gates the onset of puberty and regulates reproductive function throughout life. Kisspeptin-10 retains full biological activity at GPR54 and is the most commonly used research form due to its smaller size and ease of synthesis compared to the full 54-amino-acid kisspeptin-54 precursor. Its role extends beyond reproduction: kisspeptin neurons integrate metabolic signals (leptin, insulin, glucose) and relay this information to GnRH neurons, making kisspeptin a key node linking nutritional status to rep
Mechanism of Action
Kisspeptin-10 acts as an agonist at GPR54 (KISS1R), a Gαq/11-coupled receptor expressed on GnRH neurons in the hypothalamus, pituitary gonadotrophs, and peripheral tissues. GPR54 activation stimulates phospholipase C (PLC), generating IP3 and DAG, which mobilize intracellular calcium and activate PKC. This signaling cascade depolarizes GnRH neurons, triggering GnRH release into the hypothalamic-pituitary portal circulation. GnRH then stimulates pituitary gonadotrophs to release LH and FSH, which act on the gonads to stimulate sex steroid production and gametogenesis. This complete HPG axis activation makes kisspeptin-10 a powerful research tool for studying reproductive endocrinology, puber
Research Evidence
- Master regulator of the HPG axis — gates puberty onset and regulates reproductive function
- GPR54 activation triggers GnRH → LH/FSH cascade with robust, dose-dependent responses
- Integrates metabolic signals (leptin, insulin) to link nutritional status to reproductive function
- Stimulates pituitary GH secretion in addition to LH/FSH (dual neuroendocrine activity)
- Anti-tumor and anti-angiogenic properties via c-Src/FAK signaling in cancer models
Bottom line: KLOW is a high-complexity research blend for advanced metabolic research. As with all blends, direct studies on this specific combination are limited; the rationale is based on the complementary mechanisms of the three individual components. All three are research-only compounds. This is one of the most scientifically ambitious formulations in the Purgo Labs catalog.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for KLOW are detailed in the full compound profile. See also: Dosage guide for KLOW.
Sourcing & Quality
KLOW is available from Purgo Labs with third-party COA verification and research-grade purity standards. View KLOW at Purgo Labs.